Are you Lin-Yun Wang?

Claim your profile

Publications (3)2.55 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To explore the anti-tumor efficacy of anti- vascular endothelial growth factor (VEGF) McAb 5-fluorouracil (5-FU) loaded polylactic acid (PLA) nanoparticles (NPS) in human gastric carcinoma xenografts of nude mice. Anti-VEGF McAb 5-FU loaded PLA NPS were made by ultrasound emulsification. Nude mice model of human gastric carcinoma xenografts was established. Therapeutic effects of drugs on human gastric carcinoma xenografts and side effects concerned were observed. The tumor inhibition rates of control group, nanosphere without 5-FU group, 5-FU (20 mg/kg) group, anti-VEGF McAb nanosphere without 5-FU group, anti-VEGF McAb group, nanosphere with 5-FU group, 5-FU (20 mg/kg) combined with anti-VEGF McAb group, anti-VEGF McAb 5-FU loaded nanosphere group was 0, 6.61%, 24.26%, 27.94%, 35.29%, 37.50%, 39.71% and 52.21% respectively, and there were no significant differences between anti-VEGF McAb 5-FU loaded nanosphere group and nanosphere group without 5-FU in WBC count, serum alanine transferase level or creatinine level. Compared with control group and anti-VEGF McAb 5-FU loaded nanosphere group, the 5-FU group decreased by 34.43% and 37.38% respectively in WBC count (P< 0.05), and increased by 93.17% and 66.56% respectively in alanine transferase. There were significant differences between experimental groups and control group in apoptosis index, especially between anti-VEGF McAb 5-FU loaded nanosphere group and control group (P< 0.05). The microvessel density (MVD) of experimental groups containing anti-VEGF McAb was significantly lower than that of control group or groups containing 5-FU (P< 0.05). Anti-VEGF McAb 5-FU loaded nanosphere can increase the tumor inhibitory rate of 5-FU, induce apoptosis by inhibiting tumor angiogenesis with less side effect, and then enhance therapeutic effect, which indicate its potential as a novel, safe nano-tumor-targeting drug.
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 09/2007; 10(5):482-5.
  • [Show abstract] [Hide abstract]
    ABSTRACT: CD4+CD25+ regulatory T cells play a crucial role in the immunosuppression of gastric cancer patients, but the mechanism is still unknown. This study was to investigate the secretion of intracellular and extracellular cytokines interferon-gamma (IFN-gamma), interleukin-4 (IL-4), IL-10 and tumor growth factor-beta (TGF-beta) from CD4+CD25+ regulatory T cells in gastric cancer patients, and evaluate their roles in the immunosuppression of gastric cancer. Peripheral blood mononuclear lymphocytes of gastric cancer patients were prepared routinely. CD4+CD25+ T cells and CD4+CD25- T cells were isolated by magnetic activated cell sorting (MACS) method, and identified by flow cytometry. The cytokine secretion of CD4+CD25+ T cells and CD4+CD25- T cells was detected by intracellular analysis of cytokine production (IFN-gamma, IL-4 and IL-10) and ELISA (IFN-gamma, IL-10 and TGF-beta). The proportion of CD4+CD25+ T cells to CD4+ T cells was significantly higher in gastric cancer patients than in healthy controls (P<0.05). After 96-hour cell culture, no matter in gastric cancer patients or in healthy controls, the secretion of IL-10 and TGF-beta were significantly higher from CD4+CD25+ T cells than from CD4+CD25- T cells (P<0.05), but the secretion of IFN-gamma was significantly lower from CD4+CD25+ T cells than from CD4+CD25- T cells (P<0.05). The immunosuppression of CD4+CD25+ regulatory T cells in gastric cancer may relate to suppressive cytokines, especially TGF-beta.
    Ai zheng = Aizheng = Chinese journal of cancer 03/2007; 26(3):270-3.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the major clinical symptom, etiology, and diagnostic method in patients with primary small intestinal disease in order to improve the diagnosis. A total of 309 cases with primary small intestinal disease were reviewed, and the major clinical symptoms, etiology, and diagnostic methods were analyzed. The major clinical symptoms included abdominal pain (71%), abdominal mass (14%), vomiting (10%), melaena (10%), and fever (9%). The most common disease were malignant tumor (40%). diverticulum (32%) and benign tumor (10%). Duodenal disease was involved in 36% of the patients with primary small intestinal diseases. The diagnostic rate for primary small intestinal diseases by double-contrast enteroclysis was 85.6%. Abdominal pain is the most common clinical symptom in patients with primary small intestinal disease. Malignant tumors are the most common diseases. Duodenum was the most common part involved in small intestine. Double-contrast enteroclysis was still the simplest and the most available examination method in diagnosis of primary small intestinal disease. However, more practical diagnostic method should be explored to improve the diagnostic accuracy.
    World Journal of Gastroenterology 10/2004; 10(17):2585-7. · 2.55 Impact Factor